On day 10 post tumor challenge, when levels of the three pro-inflammatory cytokines were still low (Fig. 1C), we began injections of validated blocking antibodies targeting TNFα, IL-1β, IL-6R, or no blockade [14–16]. This evidence concerns the gene IL6R and neoplasm.